Pfizer Property, Plant, and Equipment 2010-2024 | PFE
Pfizer property, plant, and equipment from 2010 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
- Pfizer property, plant, and equipment for the quarter ending September 30, 2024 was $18.541B, a 3.8% increase year-over-year.
- Pfizer property, plant, and equipment for 2023 was $18.94B, a 16.38% increase from 2022.
- Pfizer property, plant, and equipment for 2022 was $16.274B, a 9.35% increase from 2021.
- Pfizer property, plant, and equipment for 2021 was $14.882B, a 8.27% increase from 2020.
Pfizer Annual Property, Plant, and Equipment
(Millions of US $) |
| 2023 |
$18,940 |
| 2022 |
$16,274 |
| 2021 |
$14,882 |
| 2020 |
$13,745 |
| 2019 |
$12,969 |
| 2018 |
$13,385 |
| 2017 |
$13,865 |
| 2016 |
$13,318 |
| 2015 |
$13,766 |
| 2014 |
$11,762 |
| 2013 |
$12,397 |
| 2012 |
$13,213 |
| 2011 |
$15,921 |
| 2010 |
$18,645 |
| 2009 |
$22,780 |
Pfizer Quarterly Property, Plant, and Equipment
(Millions of US $) |
| 2024-09-30 |
$18,541 |
| 2024-06-30 |
$18,957 |
| 2024-03-31 |
$18,803 |
| 2023-12-31 |
$18,940 |
| 2023-09-30 |
$17,862 |
| 2023-06-30 |
$17,488 |
| 2023-03-31 |
$17,052 |
| 2022-12-31 |
$16,274 |
| 2022-09-30 |
$15,441 |
| 2022-06-30 |
$15,244 |
| 2022-03-31 |
$15,109 |
| 2021-12-31 |
$14,882 |
| 2021-09-30 |
$14,436 |
| 2021-06-30 |
$14,224 |
| 2021-03-31 |
$14,011 |
| 2020-12-31 |
$13,745 |
| 2020-09-30 |
$14,403 |
| 2020-06-30 |
$14,113 |
| 2020-03-31 |
$14,040 |
| 2019-12-31 |
$12,969 |
| 2019-09-30 |
$13,701 |
| 2019-06-30 |
$13,521 |
| 2019-03-31 |
$13,467 |
| 2018-12-31 |
$13,385 |
| 2018-09-30 |
$14,036 |
| 2018-06-30 |
$13,919 |
| 2018-03-31 |
$13,971 |
| 2017-12-31 |
$13,865 |
| 2017-09-30 |
$13,505 |
| 2017-06-30 |
$13,386 |
| 2017-03-31 |
$13,238 |
| 2016-12-31 |
$13,318 |
| 2016-09-30 |
$13,284 |
| 2016-06-30 |
$13,609 |
| 2016-03-31 |
$13,584 |
| 2015-12-31 |
$13,766 |
| 2015-09-30 |
$13,695 |
| 2015-06-30 |
$11,432 |
| 2015-03-31 |
$11,527 |
| 2014-12-31 |
$11,762 |
| 2014-09-30 |
$12,032 |
| 2014-06-30 |
$12,179 |
| 2014-03-31 |
$12,347 |
| 2013-12-31 |
$12,397 |
| 2013-09-30 |
$12,359 |
| 2013-06-30 |
$12,443 |
| 2013-03-31 |
$13,950 |
| 2012-12-31 |
$13,213 |
| 2012-09-30 |
$14,606 |
| 2012-06-30 |
$14,756 |
| 2012-03-31 |
$16,192 |
| 2011-12-31 |
$15,921 |
| 2011-09-30 |
$17,721 |
| 2011-06-30 |
$18,281 |
| 2011-03-31 |
$18,833 |
| 2010-12-31 |
$18,645 |
| 2010-09-30 |
$19,450 |
| 2010-06-30 |
$20,041 |
| 2010-03-31 |
$21,651 |
| 2009-12-31 |
$22,780 |
| 2009-09-30 |
$13,173 |
| 2009-06-30 |
$13,194 |
| 2009-03-31 |
$12,936 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
